Download the meeting impression of this PACE symposium during EDTA-ERA 2018, that explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

This summary of the presentation by prof. Baigent compares three new trials on SGLT2 inhibition to address the question whether SGLT2 inhibitors have any value for patients with established CKD.

This summary of the presentation by prof. Groop illustrates potential underlying mechanisms of the CV and renal protection seen with SGLT2 inhibition.

This summary of the presentation by prof. Wanner illustrates key lessons from the EMPA-REG OUTCOME trial focusing on the effect of empagliflozin on renal and cardiovascular (CV) events.

Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants